Response to Comments: MolDX: Plasma-Based Genomic Profiling in Solid Tumors

The provided document is an administrative Response to Comments for MolDX LCD DL38065 (Plasma-Based Genomic Profiling in Solid Tumors) and contains only procedural dates (comment period 05/07/2019–06/21/2019; notice period begins 06/11/2020; effective 07/27/2020). No clinical coverage indications, exclusions, documentation requirements for claims, or frequency limits were included in the excerpt; consult the full LCD DL38065 to extract actionable coverage criteria.

"This document is a response to comments on MolDX LCD DL38065 (Plasma-Based Genomic Profiling in Solid Tumors); comment period 05/07/2019–06/21/2019; notice period begins 06/11/2020 and becomes effe..."

Sign up to see full coverage criteria, indications, and limitations.